MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.11% for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-02-23
- MANNKIND CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 3.11%, a 23.90% increase from fiscal 2019.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.51%, a 19.29% decline from fiscal 2018.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.11%, a 46.01% increase from fiscal 2017.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.13%, a 18.33% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|
| 2020-12-31 | 3.11% 10-K · filed 2023-02-23 | 1.52% 10-K · filed 2021-02-25 |
| 2019-12-31 | 2.51% 10-K · filed 2021-02-25 | |
| 2018-12-31 | 3.11% 10-K · filed 2020-02-25 | |
| 2017-12-31 | 2.13% 10-K · filed 2019-02-26 | |
| 2016-12-31 | 1.80% 10-K · filed 2019-02-26 | |
| 2015-12-31 | 1.86% 10-K · filed 2018-02-27 | |
| 2014-12-31 | 2.11% 10-K · filed 2017-03-16 | |
| 2013-12-31 | 1.82% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 1.16% 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |